Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBIT Margin (2017 - 2026)

Akebia Therapeutics has reported EBIT Margin over the past 9 years, most recently at 14.84% for Q4 2025.

  • Quarterly EBIT Margin rose 1593.0% to 14.84% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9.95% through Dec 2025, up 4146.0% year-over-year, with the annual reading at 9.95% for FY2025, 4146.0% up from the prior year.
  • EBIT Margin was 14.84% for Q4 2025 at Akebia Therapeutics, down from 7.57% in the prior quarter.
  • Over five years, EBIT Margin peaked at 42.97% in Q4 2021 and troughed at 149.95% in Q2 2021.
  • The 5-year median for EBIT Margin is 25.38% (2024), against an average of 38.63%.
  • The largest YoY upside for EBIT Margin was 28977bps in 2021 against a maximum downside of -5733bps in 2021.
  • A 5-year view of EBIT Margin shows it stood at 42.97% in 2021, then crashed by -120bps to 8.73% in 2022, then skyrocketed by 128bps to 2.45% in 2023, then crashed by -1358bps to 30.77% in 2024, then skyrocketed by 52bps to 14.84% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBIT Margin are 14.84% (Q4 2025), 7.57% (Q3 2025), and 22.55% (Q2 2025).